BACKGROUND: Polymerase chain reaction (PCR) assays are the standard for detecting hepatitis C virus viremia. The transcription-mediated amplification (TMA)-based assay is more sensitive. METHODS: We retrospectively reviewed the charts of patients with a post-end of treatment (EOT) PCR-/TMA+ result to assess the clinical significance of a positive TMA result after a PCR negative EOT response or sustained viral response (SVR). Patients were divided into Group 1: PCR-/TMA+ after EOT response but during 24 week follow-up (n = 4); and Group 2: PCR-/TMA+ after SVR (n = 11). RESULTS: All Group 1 patients achieved SVR. No Group 2 patients became PCR positive or had a rise in ALT. The TMA subsequently became negative in 6/7 patients with follow-up evaluation. CONCLUSIONS: A discordant positive TMA post-EOT response or SVR did not seem to be clinically significant. This finding supports the possibility that patients with SVR have an acquired immune surveillance that prevents low-level viremia from progressing to clinical relapse.
BACKGROUND: Polymerase chain reaction (PCR) assays are the standard for detecting hepatitis C virus viremia. The transcription-mediated amplification (TMA)-based assay is more sensitive. METHODS: We retrospectively reviewed the charts of patients with a post-end of treatment (EOT) PCR-/TMA+ result to assess the clinical significance of a positive TMA result after a PCR negative EOT response or sustained viral response (SVR). Patients were divided into Group 1: PCR-/TMA+ after EOT response but during 24 week follow-up (n = 4); and Group 2: PCR-/TMA+ after SVR (n = 11). RESULTS: All Group 1 patients achieved SVR. No Group 2 patients became PCR positive or had a rise in ALT. The TMA subsequently became negative in 6/7 patients with follow-up evaluation. CONCLUSIONS: A discordant positive TMA post-EOT response or SVR did not seem to be clinically significant. This finding supports the possibility that patients with SVR have an acquired immune surveillance that prevents low-level viremia from progressing to clinical relapse.
Authors: L Comanor; F Anderson; M Ghany; R Perrillo; E J Heathcote; C Sherlock; I Zitron; D Hendricks; S C Gordon Journal: Am J Gastroenterol Date: 2001-10 Impact factor: 10.864
Authors: Chihiro Morishima; Timothy R Morgan; James E Everhart; Elizabeth C Wright; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; Anna S F Lok; Herbert L Bonkovsky; Adrian M Di Bisceglie; William M Lee; Jules L Dienstag; Marc G Ghany; David R Gretch Journal: Hepatology Date: 2006-08 Impact factor: 17.425
Authors: Chihiro Morishima; Timothy R Morgan; James E Everhart; Elizabeth C Wright; Minjun C Apodaca; David R Gretch; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; William M Lee; Anna S F Lok; Jules L Dienstag; Marc G Ghany; Teresa M Curto Journal: Hepatology Date: 2008-11 Impact factor: 17.425